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Summary
Background: Type 2 diabetes is an independent risk factor for chronic liver disease, however disease burden estimates and
knowledge of prognostic indicators are lacking in community populations.
Aims: To describe the prevalence and incidence of clinically significant chronic liver disease amongst community-based
older people with Type 2 diabetes and to determine risk factors which might assist in discriminating patients with unknown
prevalent or incident disease.
Design: Prospective cohort study.
Methods: Nine hundred and thirty-nine participants in the Edinburgh Type 2 Diabetes Study underwent investigation
including liver ultrasound and non-invasive measures of non-alcoholic steatohepatitis (NASH), hepatic fibrosis and sys-
temic inflammation. Over 6-years, cases of cirrhosis and hepatocellular carcinoma were collated from multiple sources.
Results: Eight patients had known prevalent disease with 13 further unknown cases identified (prevalence 2.2%) and 15 inci-
dent cases (IR 2.9/1000 person-years). Higher levels of systemic inflammation, NASH and hepatic fibrosis markers were asso-
ciated with both unknown prevalent and incident clinically significant chronic liver disease (all P<0.001).
Conclusions: Our study investigations increased the known prevalence of clinically significant chronic liver disease by over
150%, confirming the suspicion of a large burden of undiagnosed disease. The disease incidence rate was lower than anticipated
but still much higher than the general population rate. The ability to identify patients both with and at risk of developing clinic-
ally significant chronic liver disease allows for early intervention and clinical monitoring strategies. Ongoing work, with longer
follow-up, including analysis of rates of liver function decline, will be used to define optimal risk prediction tools.
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Introduction
Chronic liver disease (CLD) due to non-alcoholic fatty liver disease
(NAFLD) in community populations represents a major challenge
for general practitioners and a growing burden for healthcare ser-
vices.1 Of the 25% of the UK population now categorized as obese,
most will have NAFLD2 and 10% of these people have been diag-
nosed in community studies to have evidence of advanced liver
fibrosis that leads to cirrhosis.3 Of patients with cirrhosis (all
cause), 5–20% will develop hepatocellular carcinoma (HCC) in 5
years.4 Type 2 diabetes, which is increasing in frequency in paral-
lel with obesity, is strongly associated with NAFLD but data on
the progression to cirrhosis and HCC in community-based pa-
tients with diabetes is limited.
Three major independent reports have highlighted the need
for the early detection of liver disease.2,5,6 The ability to identify
patients with and at risk of developing clinically significant CLD
(CS-CLD) would promote early intervention strategies and guide
clinical follow-up, ensuring timely detection of cirrhosis where
assimilation into surveillance programmes for HCC and varices
as well as screening for cardiovascular disease has been shown
to improve patient outcomes. Despite this, the existing diagnos-
tic pathways for detection and onward referral of suspected
CLD are based on traditional liver enzyme tests which lack ac-
curacy and contribute to late diagnosis.
Using a population-based cohort of 1000 patients with Type
2 diabetes (The Edinburgh Type 2 Diabetes Study (ET2DS)7) we
employed an extensive screening programme (including liver
ultrasound and non-invasive measures of non-alcoholic steato-
hepatitis [NASH], hepatic fibrosis and systemic inflammation) for
clinically significant liver disease to investigate the true burden
of disease. Over 6-years, cases of cirrhosis, HCC and gastro-
oesophageal varices were collated from multiple sources.
Within the diabetic population annual liver enzyme checks
are commonly performed, but there are no clear and consistent
national guidelines on their application and interpretation, par-
ticularly in the community setting. Despite this, they remain
the main trigger for referral to specialist liver clinics. Using
standard liver enzyme assessment and liver ultrasound scan
(USS) to diagnose hepatic steatosis, we identified patients at po-
tential risk of CS-CLD and followed them up prospectively to
collect data on clinical outcomes.
Our aim was to describe the prevalence and incidence of CS-
CLD amongst older people with Type 2 diabetes and to deter-
mine whether the detection of abnormal liver enzyme levels
and/or the presence of hepatic steatosis on USS in people with
Type 2 diabetes might assist in discriminating those patients
who subsequently go on to develop CS-CLD. Finally, we investi-
gated a wide range of potential risk factors and biomarkers,
including complications of diabetes and markers of advanced
CLD, which might be useful in identifying at-risk subjects.
Methods
The Edinburgh Type 2 Diabetes Study
Full methods of the ET2DS have been published elsewhere.7
Briefly, in 2006/7 patients aged 60–75 years with Type 2 diabetes
were randomly selected from the Lothian Diabetes Register
(LDR), a comprehensive register of patients with diabetes living
in Lothian, Scotland, and invited to participate in the ET2DS.
One thousand and sixty-six men and women attended a
baseline research clinic and were enrolled into the study. This
study population has been shown to be largely representative of
all patients randomly selected from the LDR and therefore of
the target population of older men and women with Type 2 dia-
betes living in the general population.8
All survivors were invited to re-attend for clinical and liver
investigation at Year 1 (2007/8) and at Year 4 (2010/11) with 939
(dead n¼ 15, unable to contact n¼ 19, unwilling/unable n¼ 93)
and 831 study participants attending, respectively.
Clinical and laboratory examination
Details of all the research clinics held at the Wellcome Trust
Clinical Research Facility, Western General Hospital, Edinburgh,
UK have been described previously.7,9 In brief, fasting venous
blood sampling, physical examination and abdominal USS were
undertaken.
A liver screen (including viral hepatitis serology, alpha-feto
protein [AFP], liver autoantibodies, serum ferritin) was undertaken
if the patient met the criteria for referral to specialist Hepatology
services (see later) or if hepatic steatosis was present on USS and
the participant had never previously had a liver screen.
All biochemical analytes were measured at the time of clinic
attendance using a Vitros Fusion chemistry system (Ortho
Clinical Diagnostics, Bucks, UK) at the Western General Hospital
(Edinburgh, UK).
Biomarkers of liver injury
A wide range of hepatic biomarkers were assessed including
those indicating non-specific liver injury (liver enzymes: ala-
nine aminotransferase [ALT], aspartate aminotransferase [AST]
and gamma-glutamyl aminotransferase [GGT]), steatosis (USS-
graded liver fat10), NASH (cytokeratin-18 [CK18]), surrogate
measures of advanced portal hypertension (spleen size and
platelet count) and liver fibrosis (AST to Platelet Ratio Index
[APRI],11 AST:ALT ratio, Enhanced Liver Fibrosis [ELF] score,12
Fibrosis-4 score [FIB-4],13 hyaluronic acid [HA] and NAFLD
Fibrosis Score [NFS]14).
CK18 and ELF were measured in stored serum samples
(80C) as previously described.15
Abnormal liver enzymes were defined as: i) abnormal—greater
than the upper limit of normal (ULN)—ALT>50 U/l, AST>45 U/l,
GGT>55 U/l; ii) highly abnormal—greater than 2ULN for ALT,
AST, GGT and iii) greater than recently proposed sex specific cut-
offs for ALT—males>30 U/l, females>19 U/l.16
Serum marker panels for hepatic fibrosis were calculated as
in original publications.
Identification of liver disease
Identification of liver disease is described in Figure 1. Definite
(prevalent or incident) CS-CLD was a composite outcome
defined as a diagnosis of cirrhosis, HCC (with confirmatory radi-
ology) or gastro-oesophageal varices (with confirmatory endos-
copy) recorded in the patients’ medical records. Research study
referral criteria for referral to specialist Hepatology services
were designed in conjunction with an experienced consultant
Hepatologist (Figure 1A), prevalent and incident CS-CLD was
identified using a two-stage process across multiple sources
(Figure 1B) and CS-CLD was defined as in Figure 1C.
Data analysis
Data were analysed using SPSS v19.0 (SPSS Inc., IL). Variables
that were not normally distributed were, where necessary,
transformed and analysed on a logarithmic scale.
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We describe the prevalence (both known and unknown) at
the start of the study and subsequent incident CS-CLD. For ini-
tial analyses, all participants without known prevalent CS-CLD
were included.
Exploratory analysis of potential risk factors and biomarkers
associated with the development of advanced liver disease was
undertaken using: patient characteristics, diabetes history and
treatment, metabolic variables, established risk factors for CLD,
markers of liver injury (non-specific, steatosis, NASH, advanced
portal hypertension and liver fibrosis), and markers of systemic
inflammation. Cox regression was used to investigate the asso-
ciation of potential risk factors with CS-CLD.
Ethical approval was obtained from the Lothian Research
Ethics Committee and all subjects gave written informed consent.
Results
Subject characteristics
Participant attendance is shown in Figure 2. Clinical follow-up
data was available for all 939 Year 1 clinic attendees.
Characteristics of the study population are shown in Table 1.
Prevalent CS-CLD
Eight patients had known prevalent CS-CLD and were excluded
from the investigation of unknown prevalent disease (n¼ 931,
Figure 2A).17
Following the Year 1 investigations, 13.4% (125/931) of par-
ticipants met the research study protocol criteria as high risk
for the presence of liver disease and were referred to
Hepatology. Risk factors for referral are shown in Table 1.
Of these, 52 (41.6%) were offered an appointment at
Hepatology clinic and the remainder returned to standard care
after triage by a consultant Hepatologist. The majority of those
not seen had low level titres of positive autoantibodies (1:40)
or isolated mildly elevated liver enzymes only (<2ULN).
Of those referrals seen, 31 (59.6%) were immediately dis-
charged following initial assessment on the basis of having ei-
ther simple fatty liver with low risk for the presence of
significant liver fibrosis (according to non-invasive marker crite-
ria) and/or false positive indicators of CS-CLD (e.g. plate-
lets<150  109/l but no portal hypertension) as determined by a
consultant Hepatologist. Twenty-one participants (40.4) remain
under active Hepatology follow-up.
As a consequence of the Year 1 investigations, 13 (1.4%)
patients were diagnosed with previously unknown prevalent
CS-CLD (including one HCC, the remainder cirrhosis). The rea-
sons for their initial referral were wide-ranging.
Risk factors associated with unknown prevalent cases were
elevated liver enzymes (but not ALT), inflammatory markers,
markers of NASH and hepatic fibrosis (all P< 0.01, Tables 2 and 3).
Overall the prevalence of CS-CLD was 2.2% (known plus
unknown).
Development of incident CS-CLD
Nine hundred and eighteen patients (Figure 2B) did not have
prevalent CS-CLD.
Figure 1. Identification of liver disease. ALP, alkaline phosphatase; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CLD, chronic liver disease; CS-
CLD, clinically significant chronic liver disease; GGT, gamma-glutamyl transferase; HCC, hepatocellular carcinoma; USS, ultrasound scan. Alcohol excess was defined
as females>14 units/week, males>21 unis/week or patient disclosed history of a current or prior alcohol problem. Use of potentially hepatotoxic medication was
defined as the use of non-topical glucocorticoids for>1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the Year 1 clinic.
Strongly positive autoantibodies were defined as ASMA titre>1:160 or AMA titre>1:40.
J.R. Morling et al. | 251
Downloaded from https://academic.oup.com/qjmed/article-abstract/109/4/249/1752752
by Periodicals Department , Hallward Library, University of Nottingham user
on 18 January 2018
Over a mean follow-up period of 5.6 years (SD 1.0, total 5156
person-years) there were 15 incident cases of CS-CLD, IR 2.9/
1000 person-years. These comprised cirrhosis n¼ 14 (2.7/1000
person-years), HCC n¼ 4 (0.8/1000 person-years) and gastro-
oesophageal varices n¼ 5 (1.0/1000 person-years), with some
patients having more than one complication.
Patients identified as potentially high risk after the Year 1 in-
vestigations were more likely to develop CS-CLD than those not
thought to have liver disease (IR 10.9 vs. 1.8/1000 person-years,
P¼ 0.001). However, of the incident 15 patients that developed
CS-CLD less than half (n¼ 7, 46.7%) were identified as high risk
by the extensive liver-related investigations at the Year 1 clinic.
Of the incident HCC, only 1 (25.0%) occurred in a participant
identified through our Year 1 investigations. The majority of
cases of varices (n¼ 3, 60.0%) were identified through entry into
an endoscopic surveillance programme.
Rates of incident CS-CLD were significantly higher in those:
seen in the Hepatology clinic (IRR 18.7, 95%CI 6.5–54.0, P< 0.001),
with abnormal liver enzymes (IRR 5.7, 95%CI 2.0–16.0, P¼ 0.001)
and with very abnormal liver enzymes (IRR 16.3, 95%CI 5.2–50.9,
P< 0.001). Individuals with hepatic steatosis or elevated liver
enzymes as defined by the lower revised laboratory reference
ranges had incidence rates of CS-CLD not significantly different
to those without (IRR 2.9, P¼ 0.096 and IRR 1.2, P¼ 0.800,
respectively).
Patients with abnormal liver enzymes at the Year 1 investi-
gation were more likely to develop CS-CLD, (normal 7/776, 0.9%;
abnormal 3/113, 2.7%; very abnormal 5/26, 19.2%; P< 0.001). In
those developing CS-CLD, mean/median levels of liver enzymes
were higher, however they remained broadly within normal la-
boratory limits for transaminases (ALT 44.4 U/l, AST 46.0 U/l),
with median GGT levels above the ULN (median 62 vs. 16 U/l,
P< 0.001) (Table 2), overall 47% of those with incident CS-CLD
had normal liver enzymes (Table 3).
Tables 2 and 3 show the associations between potential risk
factors and incident CS-CLD. Known causes of liver disease
(including alcohol) were similar in both groups (P¼ 0.123).
Higher levels of markers of systemic inflammation were associ-
ated with an increased incidence of CS-CLD (ln C-reactive pro-
tein hazard ratio (HR) 1.66 P¼ 0.026, ln IL-6 HR 2.86 P¼ 0.002, ln
TNF-a HR 2.12 P¼ 0.017)
Nearly all patients (80.0%) with incident CS-CLD had hepatic
steatosis at the start of the study, although this was not statis-
tically significant. All of the continuous markers of NASH and
hepatic fibrosis (except AST:ALT ratio) were higher in those
with incident CS-CLD than in those who did not.
Figure 2. Patient flowcahrts. AFP, alpha-feto protein; ALD, alcoholic liver disease; ALT, alanine aminotransferase; AST, aspartate aminotransferase; CS-CLD, clinically sig-
nificant chronic liver disease; HA, hyaluronic acid; HBV, hepatitis B virus; LFTs, liver function tests; NAFLD, non-alcoholic fatty liver disease; PBC, primary biliary cirrhosis.
252 | QJM: An International Journal of Medicine, 2016, Vol. 109, No. 4
Downloaded from https://academic.oup.com/qjmed/article-abstract/109/4/249/1752752
by Periodicals Department , Hallward Library, University of Nottingham user
on 18 January 2018
Table 1. Study populationa
Study population
n¼923
Met Hepatology
referral criteria
n¼125
P [vs.not referred] Seen by Hepatology
services
n¼52
P [vs.not seen]
Age, years 68.9 (4.2) 69.3 (4.3) 0.224 69.3 (4.6) 0.423
Sex, % male 52.3% (483) 40.8 (51) 0.007 40.4 (21) 0.087
SIMD quintile, % I 11.4 (105) 9.6 (12) 0.041 9.6 (5) 0.031
V 34.3 (317) 31.2 (39) 25.0 (13)
Random glucose, mmol/l 6.89 (2.3) 7.60 (3.0) 0.003 7.93 (3.3) 0.021
HbA1c, % 7.20 (1.1) 7.37 (1.2) 0.046 7.69 (1.3) 0.008
HbA1c, mmol/mol 55.2 (11.7) 57.1 (12.7) 60.5 (14.6)
Duration of diabetes, %<5 years 25.7 (235) 20.0 (25) 0.124 17.3 (9) 0.191
Diabetes treatment: Diet, % 19.5 (180) 19.2 (24) 1.000 19.2 (10) 1.000
OAHA, % 64.8 (598) 63.2 (79) 0.688 59.6 (31) 0.456
Insulin, % 15.7 (145) 17.6 (22) 0.511 21.2 (11) 0.245
Retinopathy, % Mild 27.9 (254) 24.2 (30) 0.182 25.0 (13) 0.035
Moderate/severe 4.4 (40) 7.2 (9) 11.5 (6)
Chronic kidney diseaseb, % 19.6 (179) 22.8 (28) 0.393 27.5 (14) 0.149
Cardiovascular diseasec, % 36.9 (338) 37.6 (47) 0.842 38.5 (20) 0.769
BMI, kg/m2 31.3 (5.7) 31.7 (6.1) 0.411 32.0 (6.6) 0.414
Total cholesterol, mmol/l 4.4 (0.8) 4.3 (0.8) 0.021 4.1 (0.8) 0.690
Triglycerides, mmol/l 1.66 (0.9) 1.74 (1.0) 0.305 1.50 (0.6) 0.073
sBP, mmHg 138.2 (18.5) 140.6 (18.6) 0.115 138.7 (17.1) 0.845
Known risk factor for liver diseased, % 20.9 (193) 31.2 (39) 0.004 34.6 (18) 0.021
Alcohol excesse, % 12.8 (118) 20.8 (26) 0.006 21.2 (11) 0.084
Hepatotoxic medicationf, % 9.2 (6) 10.4 (13) 0.618 11.5 (6) 0.467
Positive autoantibodiesg, % 0.7 (6) 3.2 (4) 0.005 3.8 (2) 0.046
aValues are mean (SD), median (IQR) or % (n). BMI, body mass index; IQR, inter-quartile range; OAHA, oral anti-hyperglycaemic agent; sBP, systolic blood pressure; SD,
standard deviation; SIMD, Scottish Index of Multiple Deprivation.
bDefined as estimated glomerular filtration rate<60 ml/min.
cDefined as of myocardial infarction, angina, coronary intervention, intermittent claudication, peripheral artery intervention, stroke, transient ischaemic attack or ca-
rotid endarterectomy.
dDefined as any of d–f later.
eDefined as females>14 units/week, males>21 unis/week or patient disclosed history of a current or prior alcohol problem.
fDefined as the use of (non-topical) glucocorticoids for>1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the liver assessment.
gDefined as ASMA titre>1:160 or AMA titre>1:40.
Table 2. Potential demographic, diabetes and metabolic risk factors for the development of CS-CLDa
No CS-CLD
n¼903
Unknown
prevalent CS-CLD n¼13
OR (95% CI) for unknown
prevalent CS-CLD
P Incident
CS-CLD n¼15
HR (95% CI) for
incident CS-CLD
P
Age, years 68.9 (4.2) 69.5 (4.9) 1.04 (0.91,1.18) 0.600 69.8 (4.1) 1.07 (0.94,1.21) 0.306
Sex, % male 52.5 (474) 30.8 (4) 2.49 (0.76,8.13) 0.132 40.0 (6) 1.93 (0.69,5.45) 0.213
SIMD quintile: I, % 11.2 (101) 7.7 (1) 33.3 (5) Ref
V,% 34.9 (315) 0 (0) 26.7 (4) 0.26 (0.07,0.97) 0.044
Duration of diabetes>5 years, % 73.7 (660) 76.9 (10) 1.19 (0.32,4.35) 0.796 93.3 (14) 5.30 (0.70,40.34) 0.107
Fasting glucose, mmol/l 6.87 (2.3) 7.53(3.2) 1.11 (0.91,1.35) 0.301 6.98 (2.8) 1.21 (0.78,1.88) 0.405
HbA1c, % 7.19 (1.1) 7.34 (0.8) 1.13 (0.70,1.84) 0.615 7.53 (1.5) 1.02 (0.98,1.06) 0.405
mmol/mol 55.1 (11.6) 56.7 (8.3) 1.01 (0.97,1.06) 58.8 (15.9)
Diabetes treatment: Diet, % 19.7 (178) 15.4 (2) Ref 6.7 (1) Ref
OAHA, % 65.1 (588) 46.2 (6) 1.06 (0.22,5.15) 0.943 53.3 (8) 2.50 (0.31,20.0) 0.388
Insulin, % 15.2 (137) 69.2 (9) 2.60 (0.47,14.4) 0.274 40.0 (6) 9.08 (1.09,75.5) 0.041
BMI, kg/m2 31.2 (5.6) 33.4 (6.7) 1.06 (0.98,1.16) 0.161 34.8 (7.4) 1.09 (1.02,1.17) 0.016
Cholesterol, mmol/l 4.2 (0.8) 3.9 (0.5) 0.68 (0.32,1.43) 0.310 3.9 (0.8) 0.66 (0.33,1.34) 0.248
Triglycerides, mmol/l 1.67 (0.9) 1.25 (0.3) 0.39 (0.14,1.11) 0.078 1.46 (0.4) 0.70 (0.32,1.54) 0.371
CRPb, mg/l 1.69 (0.8–3.9) 2.72 (1.4–11.6) 1.83 (1.14,2.94) 0.013 3.98 (1.9–13.6) 1.66 (1.06,2.60) 0.026
aValues are % (n), ORs and HRs. CRP, C-reactive protein; CS-CLD, clinically significant chronic liver disease; HR, hazard ratio; OR, odds ratio; SD, standard deviation;
SIMD, Scottish Index of Multiple Deprivation. CS-CLD defined as clinically significant disease: incident cirrhosis, HCC or gastro-oesophageal varices.
bAnalysed on the Ln scale: ORs and HRs for a one unit increase in the ln of the risk factor.
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Conclusions
We conducted the only large prospective community-based
study of older patients with Type 2 diabetes. The prevalence of
CS-CLD at baseline was 2.2% (0.9% diagnosed clinically prior to
enrolment and 1.4% identified by study investigations). The in-
cidence of CS-CLD was 1.4% over nearly 6 years (IR 2.9/1000 per-
son-years).
Existing estimates of CS-CLD frequency are limited by reli-
ance on confirmatory liver biopsy in secondary care populations
or in community-based cohorts by the use of a single screening
modality (e.g. FibroTest,18 transient elastography19) each with
their own challenges; e.g. liver enzymes have low diagnostic ac-
curacy, non-invasive fibrosis markers (e.g. ELF, NFS) have poor
positive predictive values for later stages of CLD,12,14 ICD codes
only identify hospitalized cases with decompensation and bi-
opsy has marked ascertainment bias. Accordingly, in the gen-
eral population, the prevalence of advanced fibrosis in NAFLD
ranged from 0 to 12% in a single study depending on the
markers used,20 and there is even greater discordance between
different studies on CS-CLD prevalence. Therefore, we used a
multimodal approach to comprehensively phenotype our cases
and maximize detection CS-CLD.
Our findings support the suggestion that NAFLD is an under-
diagnosed chronic disease21 despite patients with Type 2 diabetes
having, as a minimum, annual clinical reviews including liver en-
zyme tests. Our multimodal diagnostic approach increased the
prevalence by more than 150% through the diagnosis of unknown
CS-CLD, of which almost 70% was attributable to NAFLD.
However, it was a labour intensive process with 14% of the study
participants referred to a consultant Hepatologist. In the majority
of these patients, simple laboratory tests were abnormal (e.g. liver
enzymes above the ULN, low platelet count) although, typically,
values were only marginally elevated.
Reassuringly, despite a relatively high prevalence of uncom-
plicated NAFLD at Year 1 there were only a small number of
patients who went on to develop incident CS-CLD after 6 years
(2.9/1000 person-years). In 103 NAFLD patients followed by
Adams et al.22 for a mean of 3.2 years, the fibrosis progression rate
was 0.35 stages/year in those with diabetes. This is high com-
pared to our cohort as it equates to a potential 2-stage advance-
ment over the 6 year follow-up of our cohort in those with
NAFLD. In NASH populations, 32% of subjects progressed fibrosis
score over 3 years23 and 31% had progressive fibrosis,24 although
no participant developed cirrhosis during 4 years of follow-up.
The only aspect of diabetes history to be associated with the
development of CS-CLD was the use of insulin (HR 9.08).
Hyperinsulinemia associated with T2DM is a risk factor for
NASH, hepatic fibrosis and HCC. Insulin stimulates hepatic stel-
late cell proliferation and collagen synthesis in vitro and there-
fore, by extension, exogenous insulin therapy could promote
liver fibrosis in vivo.25 Our data reinforces the known associ-
ation between the presence of diabetes and increased the risk of
HCC.26 Moreover, Scottish Cancer Registry data showed that
within the whole Scottish population aged 60–75 the IR for liver-
related cancer (including biliary) in 2012 was 0.3/1000 person-
years,27 which is substantially lower than the rate for HCC alone
in our cohort (0.8/1000 person-years).
Participants in the least deprived Scottish Index of Multiple
Deprivation (SIMD) quintile had an incidence rate of CS-CLD
74% lower than those in the most deprived quintile. This un-
adjusted finding may represent confounding by other factors
Table 3. Potential liver injury related risk factors for the development of CS-CLDa
No CS-CLD
n¼903
Unknown
prevalent
CS-CLD n¼13
OR (95% CI)
for unknown
prevalent CS-CLD
P Incident
CS-CLD
n¼15
HR (95% CI)
for incident
CS-CLD
P
ALT, U/l 33.3 (12.7) 39.0 (12.6) 1.03 (1.00–1.06) 0.108 44.4 (23.6) 1.04 (1.01,1.06) 0.002
ALT>50 U/l, % 7.8 (70) 23.1 (3) 3.56 (0.96,13.2) 0.058 40.0 (6) 6.69 (2.38,18.8) <0.001
AST, U/l 30.0 (9.5) 49.7 (12.6) 1.09 (1.06–1.13) <0.001 46.0 (23.7) 1.07 (1.04,1.09) <0.001
AST>45 U/l, % 6.8 (61) 69.2 (9) 30.8 (9.22,102.9) <0.001 40.0 (6) 8.30 (2.94,23.43) <0.001
GGTb, U/l 16.0 (10.0–26.0) 55.0 (34.0–103.0) 5.35 (2.91,9.83) <0.001 62.0 (21.5–185.0) 3.56 (2.17,5.83) <0.001
GGT>55 U/l, % 7.9 (71) 69.2 (9) 26.2 (7.87,87.1) <0.001 53.3 (8) 13.2 (4.79,36.6) <0.001
CK18b, U/l 100.6 (76.2–135.5) 152.7 (143.1–207.9) 3.42 (1.59,7.34) 0.002 127.6 (83.4–586.5) 4.10 (2.08,8.06) <0.001
Hepatic steatosis, % 56.8 (513) 46.2 (6) 0.65 (0.22,1.95) 0.445 80.0 (12) 2.93 (0.83,10.38) 0.096
APRI* 0.24 (0.19–0.32) 0.67 (0.35–0.92) 87.7 (20.8,369.6) <0.001 0.39 (0.29–0.88) 20.4 (6.81,61.0) <0.001
AST:ALT 0.95 (0.3) 1.33 (0.3) 2.55 (1.22,5.34) 0.013 1.10 (0.3) 1.56 (0.93,2.64) 0.094
AST:ALT ratio>1, % 35.7 (320) 76.9 (10) 6.00 (1.64,22.0) 0.007 60.0 (9) 3.67 (1.29,10.44) 0.015
ELF score 8.9 (0.8) 10.9 (1.0) 4.38 (2.20,8.70) <0.001 10.2 (1.0) 1.64 (1.30,2.06) <0.001
FIB4 score 1.50 (0.6) 3.96 (2.0) 7.81 (3.93,15.5) <0.001 2.56 (1.3) 4.08 (2.71,6.15) <0.001
HAb, micrg/l 50.6 (34.8–81.4) 220.3 (177.9–318.9) 16.4 (5.35,50.1) <0.001 183.2 (78.9–230.6) 5.80 (2.60,13.0) <0.001
NFS 0.40 (1.1) 1.38 (1.5) 3.99 (2.36,6.73) <0.001 0.74 (1.0) 2.18 (1.54,3.09) <0.001
Spleen>13 cm, % 4.1 (37) 69.2 (9) 52.5 (15.5,178.5) <0.001 0
Platelets<150 x 109/l, % 3.0 (27) 46.2 (6) 27.3 (8.59,86.6) <0.001 14.3 (2) 4.36 (0.97,19.6) 0.055
Known risk factor
for liver diseasec, %
20.7 (187) 30.8 (4) 1.70 (0.52,5.59) 0.488 40.0 (6) 2.44 (0.87,6.85) 0.091
Alcohol excessd, % 12.6 (113) 23.1 (3) 2.09 (0.57,7.71) 0.268 20.0 (3) 1.63 (0.46,5.77) 0.451
aValues are % (n), ORs ratios and HRs. ALT, alanine aminotransferase; APRI, Aspartate to Platelet Ration Index; AST, aspartate aminotransferase; CK18, cytokeratin-18;
CS-CLD, clinically significant chronic liver disease; ELF, Enhanced Liver Fibrosis panel; FIB4, Fibrosis-4 Score; GGT, gamma-glutamyl transferase; HA, hyaluronic acid;
HR, hazard ratio; NFS, NAFLD Fibrosis Score; OR, odds ratio. CS-CLD defined as clinically significant disease: incident cirrhosis, HCC or gastro-oesophageal varices.
bAnalysed on the Ln scale: ORs and HRs for a one unit increase in the ln of the risk factor.
cDefined as any of: alcohol excess (females>14 units/week, males>21 unis/week or patient disclosed history of a current or prior alcohol problem), hepatotoxic medi-
cation use (use of (non-topical) glucocorticoids for>1 week, isoniazid, methotrexate, amiodarone or tamoxifen within the 6 months prior to the liver assessment) or
positive autoantibodies (ASMA titre>1:160 or AMA titre>1:40).
dDefined as females>14 units/week, males>21 unis/week or patient disclosed history of a current or prior alcohol problem.
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such as alcohol and obesity. Previous studies into the relation-
ship between CLD and deprivation have found any associations
were lost after adjustment for such risk factors.28
Critically, for clinical practice, the majority of incident CS-
CLD had normal liver function tests with no steatosis. Whilst
those with abnormal liver enzymes per se were more likely to
develop CS-CLD, the mean levels of liver enzymes in those that
did were still within the normal laboratory reference range. It
may be that given the high prevalence of steatosis in the cohort
that it may add little risk of CS-CLD beyond the risk conferred
by Type 2 diabetes alone.
The main limitation to this study is the lack of liver biopsy,
although this represents an imperfect ‘gold standard’ test for
the diagnosis and staging of NAFLD and is impractical in com-
munity studies with a low prevalence of CS-CLD. Additionally,
we would argue that our non-invasive liver assessment is more
applicable to clinical practice and is unlikely to have missed CS-
CLD due to the use of validated cut-offs and robust triage for re-
ferral to a consultant Hepatologist.
This work suggests that there is little benefit in performing
liver USS of patients similar to the study cohort, where the find-
ing of hepatic steatosis could be predicted and provides no indi-
cation of future disease progression.
For the first time, we have evaluated the utility of extensive
but simple targeted investigation using routinely available clin-
ical tests to identify those at high risk of both immediate and fu-
ture CS-CLD. We plan to conduct longer term follow-up to
capture future incident liver-related events. Of particular inter-
est will be how the rate of change of potential biomarkers in
earlier stages of CLD can be used to predict future development
of CS-CLD.
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